<DOC>
	<DOCNO>NCT00003027</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Interleukin-2 may stimulate person 's white blood cell kill melanoma cell . Interferon alfa may interfere growth tumor cell . It yet know whether combination chemotherapy plus interleukin-2 interferon alfa effective combination chemotherapy alone metastatic melanoma . PURPOSE : Randomized phase III trial compare combination chemotherapy without interleukin-2 interferon alfa treat patient metastatic melanoma treat surgery .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Interleukin-2 Interferon Alfa Treating Patients With Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare response rate , duration response , survival rate patient metastatic malignant melanoma treat cisplatin , vinblastine , dacarbazine without interleukin-2 interferon alfa-2b . - Determine toxic effect regimens patient population . OUTLINE : This randomize study . Patients stratify accord performance status ( 0 vs 1 ) , prior interferon ( yes v ) , number involve site . Patients randomize one two treatment arm . - Arm I : Patients receive cisplatin IV 30 minute daily immediately follow vinblastine IV day 1-4 . Patients also receive dacarbazine IV 60 minute day 1 follow vinblastine . - Arm II : Patients receive treatment arm I . Patients also receive interleukin 2 ( IL-2 ) IV continuously day 1-4 interferon alfa-2b subcutaneously ( SC ) daily IL-2 day 1-4 IL-2 day 5 , follow filgrastim ( G-CSF ) ( SC ) daily day 7-16 . Treatment repeat every 3 week 4 course absence disease progression unacceptable toxicity . Patients follow 6 week , every 3 month 18 month , every 6 month 18 month , annually 2 year . PROJECTED ACCRUAL : A total 482 patient accrue study within 3.5 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm surgically incurable metastatic malignant melanoma Measurable disease No active brain metastasis edema No leptomeningeal disease No ocular melanoma PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9 g/dL Hepatic : Bilirubin great 1.5 mg/dL SGOT le 3 time upper limit normal unless due liver metastases Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance least 75 mL/min Cardiovascular : No congestive heart failure No symptom coronary artery disease No serious cardiac arrhythmias No prior myocardial infarction EKG Normal cardiac stress test require following : Over 50 year age Abnormal EKG Prior history cardiac disease Pulmonary : No symptomatic pulmonary disease FEV1 great 2.0 L OR least 75 % predict 50 year age history pulmonary symptom Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No significant infection HIV negative No prior malignancy within past 5 year except basal cell squamous cell skin cancer carcinoma situ cervix No organ allografts No significant disease malignancy No seizure disorder PRIOR CONCURRENT THERAPY : Biologic therapy : No prior interleukin2 therapy metastatic disease At least 4 week since prior vaccine therapy At least 4 week since prior adjuvant immunotherapy Chemotherapy : No prior chemotherapy disease Endocrine therapy : No concurrent corticosteroid Radiotherapy : No prior radiation therapy measurable disease site unless disease clearly progressive At least 4 week since prior radiation therapy local control palliation recover Surgery : Recovered prior surgery Other : No prior systemic therapy metastatic disease At least 3 month since definitive therapy brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>stage IV melanoma</keyword>
</DOC>